

## Prevention & Therapies for Hepatitis and Chronic Liver Disease Seminars 2022

**March 19, 2022 - Raleigh, NC**

This activity was created to address the professional practice gaps listed below:

- Identifying current research studies on Hepatitis B, effective vaccines and promising therapeutic agents, which could help control the spread of the virus and reduce patient suffering.
- Identifying the early signs of Hepatitis A as many are caught off-guard about recent resurgence in many different populations and sub-groups.
- Recognizing that former HBV patients are at risk for contracting Hepatitis D.
- Applying clinical guidelines and best practice screening procedures and treatment approaches for end-stage liver disease (ESLD).
- Utilizing current and emerging technologies to determine liver disease that could reduce the need for invasive diagnostic testing.

### 1. Please respond regarding how much you agree or disagree that the gaps listed above were addressed.

	Disagree			Agree	
Participating in this educational activity changed your KNOWLEDGE in the professional practice gaps listed above. [12-3.92]	(0)	(0)	(1) 8.33%	(11)	91.67%
Participating in this educational activity changed your COMPETENCE in the professional practice gaps listed above. [12-3.92]	(0)	(0)	(1) 8.33%	(11)	91.67%
Do you feel participating in this educational activity will change your PERFORMANCE in the professional practice gaps listed above? [12-3.92]	(0)	(0)	(1) 8.33%	(11)	91.67%

### 2. Please elaborate on your previous answers. (4)

Good review of hepatology + current therapies  
the material was very relevant to my job responsibilities  
This gave me additional knowledge  
this course expanded my differential diagnosis and helped keep my treatment approaches up to date

### 3. Please evaluate the effectiveness of the following speakers in improving your knowledge, competence and/or performance. (Poor = 1, Excellent = 4)

Poor Fair Good Excellent

Sidney Barritt, IV, MD [11-3.91]	(0)	(0)	(1) 9.09%	(10) 90.91%
Andrew Muir, MD [11-4.00]	(0)	(0)	(0)	(11)100%
Elizabeth Goacher, PA-C [11-3.91]	(0)	(0)	(1) 9.09%	(10) 90.91%

#### 4. Please elaborate on your previous answers. (4)

Great lectures! Dr. Muir especially highlighted current care strategies  
each speaker was engaging and shared insights from his/her professional experience  
All were very knowledgeable  
great speakers, informative, casual speaking style,

#### 5. Please identify a change that you will implement into practice as a result of attending this educational activity (new protocols, different medications, etc.) (7)

Screening and vaccination  
Knowledge of different medications available for treatment  
different medications  
N/A  
expanded knowledge  
Alcoholic cirrhosis is now replaced with alcohol related cirrhosis  
I do not practice hepatology directly but this knowledge was very helpful as I enter the field of GI

#### 6. How certain are you that you will implement this change? (10)

Very Certain (2-  
20.00%)  
Maybe (3-  
30.00%)  
Certain (3-  
30.00%)  
N/A (2-  
20.00%)

#### 7. What topics do you want to hear more about, and what issues(s) in your practice will they address? (4)

Hemochromatosis and when someone would need to see specialist. Follow up imaging intervals after treatment for HCC  
Social and psychological care of the patient with liver disease  
PBC/PSC, autoimmune hepatitis, cholangiocarcinoma  
Psychological impacts of living with chronic liver disease to provide appropriate support

#### 8. Were the patient recommendations based on acceptable practices in medicine? (9)

Yes (9-  
100.00%)

**10. Do you think the presentation was without commercial bias?**

**(10)**

Yes <sup>(10-</sup>  
100.00%)

**12. Please provide any additional comments you may have about this educational activity. (3)**

n/a

this educational activity was highly informative and provided me with a better understanding of the pathology of liver disease(s) and treatment options

Great speakers!

**13. This seminar utilized a hybrid format where live lectures were supplemented by recorded pre and post-course presentations. What did you think of this approach and why? (6)**

I thought it was great. It was nice to do in person but have option to review online.

I prefer in person lectures

appreciate both availability

I found this to be an effective approach

It was an excellent way to get additional information shared without causing the meeting to go longer than necessary

enjoyed it

As one of the participants of this educational activity, we want to encourage you to implement those ideas that were appropriate to your healthcare environment.

This evaluation is confidential and no individual will be identified by this office (Continuing Medical Education and Professional Development). It will only be used for quality improvement.

We look forward to seeing you at future University of Louisville events. Thank you very much.



**Prevention & Therapies for Hepatitis and Chronic Liver Disease Seminars 2022**

**April 2, 2022 - Houston, TX**

This activity was created to address the professional practice gaps listed below:

- Identifying current research studies on Hepatitis B, effective vaccines and promising therapeutic agents, which could help control the spread of the virus and reduce patient suffering.
- Identifying the early signs of Hepatitis A as many are caught off-guard about recent resurgence in many different populations and sub-groups.
- Recognizing that former HBV patients are at risk for contracting Hepatitis D.
- Applying clinical guidelines and best practice screening procedures and treatment approaches for end-stage liver disease (ESLD).
- Utilizing current and emerging technologies to determine liver disease that could reduce the need for invasive diagnostic testing.

**1. Please respond regarding how much you agree or disagree that the gaps listed above were addressed.**

	Disagree		Agree	
Participating in this educational activity changed your KNOWLEDGE in the professional practice gaps listed above. [10-3.90]	(0)	(0)	(1) 10.00%	(9) 90.00%
Participating in this educational activity changed your COMPETENCE in the professional practice gaps listed above. [10-3.90]	(0)	(0)	(1) 10.00%	(9) 90.00%
Do you feel participating in this educational activity will change your PERFORMANCE in the professional practice gaps listed above? [10-3.80]	(0)	(0)	(2) 20.00%	(8) 80.00%

**2. Please elaborate on your previous answers. (7)**

Excellent state of the art

I plan to check all my > 18 y/o patients for Hep C. I will evaluate fatty liver more thoroughly and seriously

Hep B vaccination recommendations just recently changed, now everyone 19-59 yo not previously vaccinated, should get vaccinated Pts with HBV/HDV coinfection are 2-3 x more likely to develop cirrhosis, and 3-6 x higher risk of HCC

It was a fantastic review on liver disease, how to recognize it and how to manage the disease process and progression.

alot of new knowledge generated by the program

Comprehensive review of HBV and NASH

good

**3. Please evaluate the effectiveness of the following speakers in improving your knowledge, competence and/or performance. (Poor = 1, Excellent = 4)**

	Poor	Fair	Good	Excellent
Saira Khaderi, MD, MPH [10-3.90]	(0)	(0)	(1) 10.00%	(9) 90.00%
Victor Machicao, MD [10-3.70]	(0)	(0)	(3) 30.00%	(7) 70.00%
Line Hiojosa, FNP [10-3.90]	(0)	(0)	(1) 10.00%	(9) 90.00%

**4. Please elaborate on your previous answers. (7)**

Clinically relevant

Great speaker

Dr Machicao gave an excellent overview of HCC treatment and I learned about down-staging tumors to within Milan criteria to make pts eligible for transplant . Also learned about TARE. I enjoyed Dr Khaderi's lecture on PSC & PBC.

They were all very knowledgeable of the subject matter.

very well organized and clear presentatkiions

All lectures were direct to the point

good

**5. Please identify a change that you will implement into practice as a result of attending this educational activity (new protocols, different medications, etc.) (9)**

Approach to hcc

more screening for Hepatitis B and D

Checking for hepatitis D

Acute liver failure patients: test for hepatitis E, however noted there is a short window of viremia in blood. HEV sheds longer in stool but poor availability of tests

Be more cognizant of the different types of hepatitis, cirrhosis and failure.

none

screening HDV on HBV patients

**6. How certain are you that you will implement this change?**

(9)

Certain <sup>(7-</sup>  
77.78%)

Very Certain <sup>(2-</sup>  
22.22%)

**7. What topics do you want to hear more about, and what issues(s) in your practice will they address? (7)**

Nash , genetic screening

Other topics in GI.. Endoscopy, IBD, pancreatitis, etc

IBD flares in hospitalized patients and outpatient management of IBD

The were all fairly well covered.

treatment of potal hypertension

non invasive assessment of fibrosis

none

**8. Were the patient recommendations based on acceptable practices in medicine?**

(9)

Yes (9-  
100.00%)

**10. Do you think the presentation was without commercial bias?**

**(8)**

Yes (7-  
87.50%)

No (1-  
12.50%)

**12. Please provide any additional comments you may have about this educational activity. (6)**

Well conducted, audio poor on zoom call

Enjoyed it much. Look forward to future conferences

Thoroughly enjoyed it except for the facilities.

well done

Great location, convenient

good presentation

**13. This seminar utilized a hybrid format where live lectures were supplemented by recorded pre and post-course presentations. What did you think of this approach and why? (8)**

Better audio

It was good but too long

it was very good, although we had some problems with audio for the teleconference portion. Always a computer issue...

If ZOOM is going to be used for a presentation you need to be sure the volume can be adjusted to it can be appropriately heard

I think it's great. I plan to re-read, re-watch some of the presentations

It was okay.

prefer live lectures, poor attention with prerecorded material

good approach

As one of the participants of this educational activity, we want to encourage you to implement those ideas that were appropriate to your healthcare environment.

This evaluation is confidential and no individual will be identified by this office (Continuing Medical Education and Professional Development). It will only be used for quality improvement.

We look forward to seeing you at future University of Louisville events. Thank you very much.

## Prevention & Therapies for Hepatitis and Chronic Liver Disease Seminars 2022

**April 9, 2022 - Pasadena, CA**

This activity was created to address the professional practice gaps listed below:

- Identifying current research studies on Hepatitis B, effective vaccines and promising therapeutic agents, which could help control the spread of the virus and reduce patient suffering.
- Identifying the early signs of Hepatitis A as many are caught off-guard about recent resurgence in many different populations and sub-groups.
- Recognizing that former HBV patients are at risk for contracting Hepatitis D.
- Applying clinical guidelines and best practice screening procedures and treatment approaches for end-stage liver disease (ESLD).
- Utilizing current and emerging technologies to determine liver disease that could reduce the need for invasive diagnostic testing.

### 1. Please respond regarding how much you agree or disagree that the gaps listed above were addressed.

	Disagree		Agree	
Participating in this educational activity changed your KNOWLEDGE in the professional practice gaps listed above. [5-4.00]	(0)	(0)	(0)	(5)100%
Participating in this educational activity changed your COMPETENCE in the professional practice gaps listed above. [6-3.83]	(0)	(0)	(1) 16.67%	(5) 83.33%
Do you feel participating in this educational activity will change your PERFORMANCE in the professional practice gaps listed above? [6-3.83]	(0)	(0)	(1) 16.67%	(5) 83.33%

### 2. Please elaborate on your previous answers. (4)

I am a new NP in the practice so the topics discussed help me understand a lot of the diseases in the liver

very informative

This was an area that needed updating in my primary care practice. It was definitely helpful.

the lecturers provided more insight on management of CLD, considering I work in liver transplant surgery

### 3. Please evaluate the effectiveness of the following speakers in improving your knowledge, competence and/or performance. (Poor = 1, Excellent = 4)

	Poor	Fair	Good	Excellent
Saro Khemichian, MD [6-4.00]	(0)	(0)	(0)	(6)100%
Sammy Saab, MD [6-3.67]	(0)	(1) 16.67%	(0)	(5) 83.33%
Vinay Sundaram, MD [5-4.00]	(0)	(0)	(0)	(5)100%

#### 4. Please elaborate on your previous answers. (5)

all speakers were knowledgeable and receptive to questions

n/a

the 3 speakers were just excellent, even though they all had different styles. very easy to follow and were knowledgeable regarding the subject matter.

All were very good, but I found Dr Saab style most stimulating and entertaining.

All lecturers were interactive with the audience and were very clear with the presented content. Excellent speakers

#### 5. Please identify a change that you will implement into practice as a result of attending this educational activity (new protocols, different medications, etc.) (5)

I will not start Hep C tx on pt listed for liver transplant so they can have an opportunity to receive Hep C liver

none

I do not take care of patients

More frequent testing for HCV. closer communication with my GI's. Better utilize testing.

utilization of work-up in CLD, diagnostic studies and the utility of them in clinical practice

#### 6. How certain are you that you will implement this change?

(5)

Very Certain (2-  
40.00%)

Certain (2-  
40.00%)

N/A (1-  
20.00%)

#### 7. What topics do you want to hear more about, and what issues(s) in your practice will they address? (5)

decompensated cirrhosis complications

same

DM, CKD

AIH, HH

5-10 year outcomes in liver transplant recipients, and quality of life after transplant

#### 8. Were the patient recommendations based on acceptable practices in medicine?



(6)

Yes (6-  
100.00%)

**10. Do you think the presentation was without commercial bias?**

(6)

Yes (6-  
100.00%)

**12. Please provide any additional comments you may have about this educational activity. (5)**

none

n/a

Thank you for an excellent conference. Very well organized and I enjoyed the commercial talks also.

Didnt like starting late. Didnt much care for the moving around.

10 year post liver transplant complications

**13. This seminar utilized a hybrid format where live lectures were supplemented by recorded pre and post-course presentations. What did you think of this approach and why? (6)**

I think this is a great approach as there are topics important to some that will not fit to the time provided

very good

I think it works well. I appreciate the enduring material and the ease of using the app.

I found it effective.

Great! Loved it

information provided and presented was excellent, direct to clinical practice

As one of the participants of this educational activity, we want to encourage you to implement those ideas that were appropriate to your healthcare environment.

This evaluation is confidential and no individual will be identified by this office (Continuing Medical Education and Professional Development). It will only be used for quality improvement.

We look forward to seeing you at future University of Louisville events. Thank you very much.



UNIVERSITY OF  
**LOUISVILLE**

CONTINUING MEDICAL  
EDUCATION & PROFESSIONAL  
DEVELOPMENT

# Prevention & Therapies for Hepatitis and Chronic Liver Disease Seminars 2022

**April 30, 2022 - Denver, CO**

This activity was created to address the professional practice gaps listed below:

- Identifying current research studies on Hepatitis B, effective vaccines and promising therapeutic agents, which could help control the spread of the virus and reduce patient suffering.
- Identifying the early signs of Hepatitis A as many are caught off-guard about recent resurgence in many different populations and sub-groups.
- Recognizing that former HBV patients are at risk for contracting Hepatitis D.
- Applying clinical guidelines and best practice screening procedures and treatment approaches for end-stage liver disease (ESLD).
- Utilizing current and emerging technologies to determine liver disease that could reduce the need for invasive diagnostic testing.

## **1. Please respond regarding how much you agree or disagree that the gaps listed above were addressed.**

	Disagree		Agree	
Participating in this educational activity changed your KNOWLEDGE in the professional practice gaps listed above. [7-4.00]	(0)	(0)	(0)	(7)100%
Participating in this educational activity changed your COMPETENCE in the professional practice gaps listed above. [7-4.00]	(0)	(0)	(0)	(7)100%
Do you feel participating in this educational activity will change your PERFORMANCE in the professional practice gaps listed above? [7-4.00]	(0)	(0)	(0)	(7)100%

## **2. Please elaborate on your previous answers. (1)**

Helped me understand several concepts and disease processes related to hepatitis, alcohol and fatty liver that will absolutely help me provide better Nurse support to my patients

## **3. Please evaluate the effectiveness of the following speakers in improving your knowledge, competence and/or performance. (Poor = 1, Excellent = 4)**

	Poor	Fair	Good	Excellent
Lisa Forman, MD [7-4.00]	(0)	(0)	(0)	(7)100%
Avash Kalra, MD [7-4.00]	(0)	(0)	(0)	(7)100%
Michael Ball, PharmD [7-3.86]	(0)	(0)	(1) 14.29%	(6) 85.71%

## **4. Please elaborate on your previous answers. (1)**

All speakers were uniformly excellent and knowledgeable about the topics they spoke on.

5. Please identify a change that you will implement into practice as a result of attending this educational activity (new protocols, different medications, etc.) (4)

Will certainly be more tuned into the importance of testing for Hepatitis D and LAL after these talks. I will be more alert for subtle changes to creatinine in our sarcopenic patients at risk for HRS. I feel like I have a better knowledge base to speak on regarding liver cancers and staging criteria, which will help me explain these concepts better to my patients when discussing radiology results.

No planned change, but refreshed my viral hepatitis knowledge base.

Implementation of updated practice in screening for hepatitis B, C, and HCC.

Change screening for Hep C beginning at age 18

**6. How certain are you that you will implement this change?**

(3)

Certain <sup>(3-</sup>  
100.00%)

**7. What topics do you want to hear more about, and what issues(s) in your practice will they address? (1)**

As nurse, it would be helpful for me to hear more about topics that can help with resources for pts with alcoholism, and nutrition. Cirrhosis in pregnancy would be helpful as well.

**8. Were the patient recommendations based on acceptable practices in medicine?**

(4)

Yes <sup>(4-</sup>  
100.00%)

**10. Do you think the presentation was without commercial bias?**

(5)

Yes <sup>(5-</sup>  
100.00%)

**12. Please provide any additional comments you may have about this educational activity. (2)**

I felt badly that the providers were missing some of their slides. I feel like more breaks to walk around and stretch between presentations would have been helpful. Otherwise I felt this was a very well-organized conference!

Great conference

**13. This seminar utilized a hybrid format where live lectures were supplemented by recorded pre and post-course presentations. What did you think of this approach and why? (2)**

I thought this was a good approach, rather than make the day even longer. It allowed us to do some of the learning activities on our own time.

It was great, lectures were informative and not too long

As one of the participants of this educational activity, we want to encourage you to implement those ideas that were appropriate to your healthcare environment.

This evaluation is confidential and no individual will be identified by this office (Continuing Medical Education and Professional Development). It will only be used for quality improvement.

We look forward to seeing you at future University of Louisville events. Thank you very much.



## Prevention & Therapies for Hepatitis and Chronic Liver Disease Seminars 2022

**May 14, 2022 - Costa Mesa, CA**

This activity was created to address the professional practice gaps listed below:

- Identifying current research studies on Hepatitis B, effective vaccines and promising therapeutic agents, which could help control the spread of the virus and reduce patient suffering.
- Identifying the early signs of Hepatitis A as many are caught off-guard about recent resurgence in many different populations and sub-groups.
- Recognizing that former HBV patients are at risk for contracting Hepatitis D.
- Applying clinical guidelines and best practice screening procedures and treatment approaches for end-stage liver disease (ESLD).
- Utilizing current and emerging technologies to determine liver disease that could reduce the need for invasive diagnostic testing.

### 1. Please respond regarding how much you agree or disagree that the gaps listed above were addressed.

	Disagree		Agree	
Participating in this educational activity changed your KNOWLEDGE in the professional practice gaps listed above. [14-3.79]	(0)	(0)	(3) 21.43%	(11) 78.57%
Participating in this educational activity changed your COMPETENCE in the professional practice gaps listed above. [14-3.64]	(0)	(0)	(5) 35.71%	(9) 64.29%
Do you feel participating in this educational activity will change your PERFORMANCE in the professional practice gaps listed above? [14-3.57]	(0)	(1) 7.14%	(4) 28.57%	(9) 64.29%

**2. Please elaborate on your previous answers. (7)**

very informative for primary care on chronic liver disease and treatment.

very informative and educational

I can manage hep B and screen for HCC more effectively.

knowledge for screening and referral

Better understanding of early detection and treatment options.

My practice is little effect in this education activity. I am still not satisfy about the Delta Hepatitis

I was impressed and also overwhelmed by the advances in research since 1976, and by the nomenclature/abbreviations you GI and Disease specialist communicate with each other.

**3. Please evaluate the effectiveness of the following speakers in improving your knowledge, competence and/or performance. (Poor = 1, Excellent = 4)**

	Poor	Fair	Good	Excellent
Mazan Nourredin, MD [15-3.93]	(0)	(0)	(1) 6.67%	(14) 93.33%
Tammy Harper, PA-C [15-3.73]	(0)	(0)	(4) 26.67%	(11) 73.33%
TBD [12-3.83]	(0)	(0)	(2) 16.67%	(10) 83.33%

**4. Please elaborate on your previous answers. (9)**

very informative

Drs Fong and Sundaram were Excellent presenters with amazing knowledge

we had different speakers than mentioned above. Dr. Fong et al.

All speakers were excellent!! Thank you. It's spending my Saturday for CME.

clear presentation

Dr. Nourredin was able to present even though apparently one of the set of slides weren't his.

Dr Fong did an excellent job..

Excellent delivery and elocution by all speakers

Each speaker presented a clinical and humanistic characterization of what can now be accomplished for our patients.

**5. Please identify a change that you will implement into practice as a result of attending this educational activity (new protocols, different medications, etc.) (14)**

- Review screening protocol for hepatitis B and hepatitis C - Identify for NASH/ NAFLD na

educate pt on fatty liver finding

Better understanding of risk stratification And referrals for NASH/fibrosis

ordering and following hep b patients differently.

Start to use fibroscan to screen for fatty liver in my DM pt >55 y/o

better understanding lab results

Applying Fib-4 score

wonder about screening for Delta hepatitis in chronic Hep. B

managing hep B infection.

New screening protocols

hepatitis screening

I will be counseling patients with abnormal liver about advances in understanding how to improve their status, what has happened and positively describe what can now be done with surgical procedures, treatment, diet and careful monitoring by their PCP

New protocols

**6. How certain are you that you will implement this change?**

**(13)**

Certain <sup>(4-</sup>  
30.77%)

N/A <sup>(1-</sup>  
7.69%)

Very Certain <sup>(5-</sup>  
38.46%)

Maybe <sup>(3-</sup>  
23.08%)

**7. What topics do you want to hear more about, and what issues(s) in your practice will they address? (12)**

If possible some topics on Nutrition and Chronic Liver Disease. Thanks

dili

acute liver injury

Updates on treatment of Cardiac diseases, ACS/HF

diabetes

Hepatitis in pediatric pts

NA

covid 19 complications

n/A

CARDIOLOGY

Have been discussing liver toxic products our patient have been trying, giving them alternative with diet and lifestyle. Updating what can affect our liver would help.

NASH

**8. Were the patient recommendations based on acceptable practices in medicine?**

**(15)**

Yes <sup>(15-</sup>  
100.00%)

**10. Do you think the presentation was without commercial bias?**

**(15)**

Yes <sup>(14-</sup>  
93.33%)

No <sup>(1-</sup>  
6.67%)

**11. If you answered No on the above question, please list the topics that were biased? (1)**

pharm reps were at the side and we have lecture about Mavyret

**12. Please provide any additional comments you may have about this educational activity. (8)**

Given this is the first in person conference during our Covid pandemic, we 'd covered lots of topic. Some lectures were flying due to time. Maybe another education in 6 months to review.

Speakers were interesting and professional

very informative; good choice of venue at the Hilton in Costa Mesa, calif.

NA

The sound system need to be better, Speaker talk with low voices.

Excellent May need self quizzes after each segment

As I shared with the speakers, in 1976 I developed acute "non A, non B" Hepatitis in my 1st 6 months as a RN working in a neurosurgical specialty Hospital in the N. California Bay Area. I was ill with a fever of 105 and unable to eat, feeling very full with 2 bites. I turned quite yellow with jaundice, very weak x 3 months. So missed 3 months of work. I tested negative for Hep C when pregnant in 1983. I am a native of San Diego and would cross the California to baja California/Mexico border to: Tijuana and Tecate. So I obviously learned about infectious disease in water and from contact. Also was involved with HIV patients in the 1980's here in California and doing entrance physicals for new immigrants while working as a nurse practitioner, since 1980. My own family of cigarette smokers and heavy alcohol use helped me understand how our lifestyle affects our future liver health and cardiac state. I was with my father who, his death certificate stated, died from effects of Cirrhosis of the liver. Dad died from GI bleed out at age 79 after stopping all alcohol drinking with his 1st GI bleed 15 years before. He actually was an AA counselor to others. Then my oldest brother recently died at 76 in January 2020 from Liver cancer, which he dealt with the last 3 years of his life. He died with his son at his side, during the only 24 hours he spent in Hospice. When I had called him during one of his hospital stays, he casually said "oh I'm going home tomorrow, I'm just here to get microwaved". NOW I understand what he meant. Thank you all. You were able to put my personal experiences as a primary care provider (NP since 1980) in proper perspective. Now I understand how hopeful doctors of patients with newly discovered liver disease can be thanks to all you have done. Of course we check our patients history: lifestyle and Liver, Diabetes, Blood pressure and Cardiac status with every lab and every regularly scheduled visit.

It was very informative

**13. This seminar utilized a hybrid format where live lectures were supplemented by recorded pre and post-course presentations. What did you think of this approach and why? (14)**

This is very unique.

in person was excellent

Nothing specific

The app was glitchy and a bit difficult to use  
effective, sufficient.

Great approach making education more accessible.

good for reviewing after the seminar and better concentration during presentation

n/a

very good. convenient.

Good approach

yes, attended all live conference

Excellent. Change in venue was keeping us focused. The setting was easy too. I do not recall prerecorded presentation, maybe I have something more to look forward to?

yes, all good

As one of the participants of this educational activity, we want to encourage you to implement those ideas that were appropriate to your healthcare environment.

This evaluation is confidential and no individual will be identified by this office (Continuing Medical Education and Professional Development). It will only be used for quality improvement.

We look forward to seeing you at future University of Louisville events. Thank you very much.

---



## **Prevention & Therapies for Hepatitis and Chronic Liver Disease Seminars 2022**

**June 4, 2022 - Richmond, VA**

This activity was created to address the professional practice gaps listed below:

- Identifying current research studies on Hepatitis B, effective vaccines and promising therapeutic agents, which could help control the spread of the virus and reduce patient suffering.



- Identifying the early signs of Hepatitis A as many are caught off-guard about recent resurgence in many different populations and sub-groups.
- Recognizing that former HBV patients are at risk for contracting Hepatitis D.
- Applying clinical guidelines and best practice screening procedures and treatment approaches for end-stage liver disease (ESLD).
- Utilizing current and emerging technologies to determine liver disease that could reduce the need for invasive diagnostic testing.

**1. Please respond regarding how much you agree or disagree that the gaps listed above were addressed.**

	Disagree		Agree	
Participating in this educational activity changed your KNOWLEDGE in the professional practice gaps listed above. [13-3.62]	(0)	(1) 7.69%	(3) 23.08%	(9) 69.23%
Participating in this educational activity changed your COMPETENCE in the professional practice gaps listed above. [13-3.62]	(0)	(1) 7.69%	(3) 23.08%	(9) 69.23%
Do you feel participating in this educational activity will change your PERFORMANCE in the professional practice gaps listed above? [13-3.62]	(0)	(1) 7.69%	(3) 23.08%	(9) 69.23%

**2. Please elaborate on your previous answers. (7)**

I feel much more knowledgeable regarding the above topics.

I already work in hepatology practice so information didn't change my knowledge but did reinforce it.

The educational program is not likely to change my clinical practice as I am currently following all the recommendations presented.

I learned quite a bit. I always try to implement current evidence based clinical practices.

I found all the information to be very informative. I learned alot!

Having more information about standards of care and new therapies will give me information that patients need when providing teaching on medication and other therapies.

**3. Please evaluate the effectiveness of the following speakers in improving your knowledge, competence and/or performance. (Poor = 1, Excellent = 4)**

Poor Fair Good Excellent

Mitchell Schiffman, MD [13-4.00]	(0)	(0)	(0)	(13)100%
Josmoshan Bajaj, MD [13-4.00]	(0)	(0)	(0)	(13)100%
Sarah Hubbard, PC-C [13-4.00]	(0)	(0)	(0)	(13)100%

#### 4. Please elaborate on your previous answers. (6)

Great speakers

Excellent speakers.

All three were extremely knowledgeable in the subject matter and all were easy to understand and follow. Who knew Dr. Bajaj had such a good sense of humor.

All presenters were very knowledgeable in the subjects they presented.

All great and knowledgeable speakers

Knowledge and was able to answers questions with confidence

#### 5. Please identify a change that you will implement into practice as a result of attending this educational activity (new protocols, different medications, etc.) (11)

HDV screen

When to screen for hep D and E. Also, understanding the role the immune response has in alcohol associated hepatitis and when to use prednisone; also understanding the importance of nutrition in the treatment of alcohol associated hepatitis.

I may incorporate using some online tools. Also, I will encourage nutrition even more for my Alcoholic Hepatitis patients.

N/A

Not really going to change much. I guess the biggest take away for me was superinfection with Hep D and to watch for that jump in ALP.

The seminar re-enforced my clinical practices.

none

Screen more for hep C

To recognize different disease processes that I may not have known about before attending this conference.

Adding information to teaching materials for my patients

Screwing for hdv

**6. How certain are you that you will implement this change?**

(10)

Maybe <sup>(1-</sup>  
10.00%)

Certain <sup>(3-</sup>  
30.00%)

Very Certain <sup>(5-</sup>  
50.00%)

N/A <sup>(1-</sup>  
10.00%)

**7. What topics do you want to hear more about, and what issues(s) in your practice will they address? (7)**

? NASH HE RESEARCH

Everything that I wanted to know more about was addressed in this seminar - was very pleased with everything and feel I learned many things that will change/affect the way I practice.

I would like to learn more about clinical trials.

Need more information on weight loss for NAFLD patient's and how we can actually set them up for success.

I am really interested in emerging treatment for PSC. The seminar didn't really touch on fecal microbiota transplant.

I am very interested in emerging therapies for PSC. The seminar didn't really touch on fecal microbiota transplant for example.

Locoregional therapies for HCC - add to my knowledge Treatment of ulcerative colitis in post transplant patient - add to my knowledge

**8. Were the patient recommendations based on acceptable practices in medicine?**

(10)

Yes <sup>(10-</sup>  
100.00%)

**10. Do you think the presentation was without commercial bias?**

(10)

Yes <sup>(9-</sup>  
90.00%)

No <sup>(1-</sup>  
10.00%)

**12. Please provide any additional comments you may have about this educational activity. (6)**

Great 1 day conference.

See #7 above

Thank you.

Really top notch!. Probably need to cut back on the COVID lecture.

Very good overall. All presenters were easy to understand and the information was relative. This is the second evaluation of the course from me because I am having a hard time retrieving the appropriate CMEs. I rushed through this one....

Really enjoyed it for a In all day Saturday conference

**13. This seminar utilized a hybrid format where live lectures were supplemented by recorded pre and post-course presentations. What did you think of this approach and why? (10)**

Excellent, reviewed prior to lecture.

I really like this approach as I am able to go back and listen to the pre-recorded presentations for clarification if needed.

This was great.

I enjoyed this seminar and thought it provided good information in an easy to understand format.

This does not apply. All lecture were live. I did like the "industry" component and information.

Not applicable. All presentations were live.

I always find a live lecture to provide the best learning environment.

I liked the ability to earn good amount of CME with one day in person lecture.

It was a very professional and informative seminar and was very satisfied with the approach.

Loved it! Great way to provide information before conference and reinforce knowledge

**As one of the participants of this educational activity, we want to encourage you to implement those ideas that were appropriate to your healthcare environment.**

This evaluation is confidential and no individual will be identified by this office (Continuing Medical Education and Professional Development). It will only be used for quality improvement.

We look forward to seeing you at future University of Louisville events. Thank you very much.



## Prevention & Therapies for Hepatitis and Chronic Liver Disease Seminars 2022

### June 11, 2022 - Louisville, KY

This activity was created to address the professional practice gaps listed below:

- Identifying current research studies on Hepatitis B, effective vaccines and promising therapeutic agents, which could help control the spread of the virus and reduce patient suffering.
- Identifying the early signs of Hepatitis A as many are caught off-guard about recent resurgence in many different populations and sub-groups.
- Recognizing that former HBV patients are at risk for contracting Hepatitis D.
- Applying clinical guidelines and best practice screening procedures and treatment approaches for end-stage liver disease (ESLD).
- Utilizing current and emerging technologies to determine liver disease that could reduce the need for invasive diagnostic testing.

1. Please respond regarding how much you agree or disagree that the gaps listed above were addressed.

	Disagree			Agree
Participating in this educational activity changed your KNOWLEDGE in the professional practice gaps listed above. <a href="#">[14-4.00]</a>	(0)	(0)	(0)	(14)100%

Participating in this educational activity changed your COMPETENCE in the professional practice gaps listed above. [14-3.93]

(0)	(0)	(1) 7.14%	(13) 92.86%
-----	-----	-----------	-------------

Do you feel participating in this educational activity will change your PERFORMANCE in the professional practice gaps listed above? [14-3.93]

(0)	(0)	(1) 7.14%	(13) 92.86%
-----	-----	-----------	-------------

## 2. Please elaborate on your previous answers. (5)

na

Great information and presentation for new Transplant Coordinator education

I thought every presentation gave new knowledge and insight into the liver and disease associated

excellent symposim

--

## 3. Please evaluate the effectiveness of the following speakers in improving your knowledge, competence and/or performance. (Poor = 1, Excellent = 4)

	Poor	Fair	Good	Excellent
Craig McClain, MD [14-3.93]	(0)	(0)	(1) 7.14%	(13) 92.86%
Matt Cave, MD [14-3.86]	(0)	(0)	(2) 14.29%	(12) 85.71%
Anotosh Barve, MD, PhD [14-4.00]	(0)	(0)	(0)	(14) 100%
Barbra Cave, PhD, APRN [14-3.79]	(0)	(1) 7.14%	(1) 7.14%	(12) 85.71%
Loretta Jophlin, MD, PhD [14-4.00]	(0)	(0)	(0)	(14) 100%

## 4. Please elaborate on your previous answers. (7)

Dr. Barve's 1st name is spelled incorrectly, it should be Ashutosh.

na

Great presence and knowledge of all speakers

Dr. Cave seemed pre-occupied with first presentation Barbara Cave spoke very rapidly. all information was very helpful

very knowledgeable speakers

great faculty

Great faculty

**5. Please identify a change that you will implement into practice as a result of attending this educational activity (new protocols, different medications, etc.) (9)**

Not using AFP as a definitive diagnostic test for Hcc

medication to treat pain. How to treat HE

Comfort level with reviewing hepatitis lab values

Will be more aware of medications patient should take with diagnoses that were discussed: PBC, PSC, etc.

Educate pts on lifestyle modifications for NAFLD

I learned more about tests to order

No change in current practice, but did provide ideas for clinic projects, abstracts

improved treatment of hcc/naflld

--

**6. How certain are you that you will implement this change?**

**(10)**

Very Certain <sup>(6-</sup>  
60.00%)

Certain <sup>(4-</sup>  
40.00%)

**7. What topics do you want to hear more about, and what issues(s) in your practice will they address? (9)**

Hcc, hep A, he

How to treat all these conditions in elderly population in nursing home

Liver failure and treatment

Liver transplantation and recurrence of disease post-transplant

Liver disease in women

Hepatitis B/D

NASH continued.

more on alcoholic liver disease

--

**8. Were the patient recommendations based on acceptable practices in medicine?**

**(13)**

Yes (13-  
100.00%)

**10. Do you think the presentation was without commercial bias?**

**(13)**

Yes (13-  
100.00%)

**12. Please provide any additional comments you may have about this educational activity. (4)**

na

Well organized with experienced presenters.

nonr

**13. This seminar utilized a hybrid format where live lectures were supplemented by recorded pre and post-course presentations. What did you think of this approach and why? (8)**

I prefer just live lectures. I enjoy the group participation

na

Not sure this was a hybrid format?

I like option of viewing online content on my time so that the live conference does not have to go as long.

I liked it

n/a for presentation attended

liked it

Yes, I think this would be good. However, we had enough faculty to cover the diverse topics.



As one of the participants of this educational activity, we want to encourage you to implement those ideas that were appropriate to your healthcare environment.

This evaluation is confidential and no individual will be identified by this office (Continuing Medical Education and Professional Development). It will only be used for quality improvement.

We look forward to seeing you at future University of Louisville events. Thank you very much.

---



## **Prevention & Therapies for Hepatitis and Chronic Liver Disease Seminars 2022**

### **September 17, 2022 - Seattle, WA**

This activity was created to address the professional practice gaps listed below:

- Identifying current research studies on Hepatitis B, effective vaccines and promising therapeutic agents, which could help control the spread of the virus and reduce patient suffering.
- Identifying the early signs of Hepatitis A as many are caught off-guard about recent resurgence in many different populations and sub-groups.
- Recognizing that former HBV patients are at risk for contracting Hepatitis D.
- Applying clinical guidelines and best practice screening procedures and treatment approaches for end-stage liver disease (ESLD).
- Utilizing current and emerging technologies to determine liver disease that could reduce the need for invasive diagnostic testing.

**1. Please respond regarding how much you agree or disagree that the gaps listed above were addressed.**

Disagree

Agree

Participating in this educational activity changed your KNOWLEDGE in the professional practice gaps listed above. [1-4.00]

(0)	(0)	(0)	(1)100%
-----	-----	-----	---------

Participating in this educational activity changed your COMPETENCE in the professional practice gaps listed above. [1-4.00]

(0)	(0)	(0)	(1)100%
-----	-----	-----	---------

Do you feel participating in this educational activity will change your PERFORMANCE in the professional practice gaps listed above? [1-4.00]

(0)	(0)	(0)	(1)100%
-----	-----	-----	---------

## 2. Please elaborate on your previous answers. (1)

I will be more zealous in offering Hep B vaccinations and referring people for treatment of Hep C. I will be more aware of NASH and advising treatments for it.

## 3. Please evaluate the effectiveness of the following speakers in improving your knowledge, competence and/or performance. (Poor = 1, Excellent = 4)

	Poor	Fair	Good	Excellent
Kris Kowdley, MD [1-4.00]	(0)	(0)	(0)	(1)100%
Charles Landis, MD, PhD [1-4.00]	(0)	(0)	(0)	(1)100%
Paula Cox-North [1-4.00]	(0)	(0)	(0)	(1)100%

## 4. Please elaborate on your previous answers. (1)

Dr. Kowdley defined and explained the different types of liver disease: NAFLD, Primary Sclerosing Cholangitis and Primary Biliary Cholangitis.

## 5. Please identify a change that you will implement into practice as a result of attending this educational activity (new protocols, different medications, etc.) (1)

Advocate for lifestyle change in persons with NAFLD i.e. use of statins, weight loss, Mediterranean diet

## 6. How certain are you that you will implement this change?

(1)

Certain <sup>(1-</sup>  
100.00%)

## 7. What topics do you want to hear more about, and what issues(s) in your practice will they address? (1)

I would like to understand the algorithth for serological testing for Hepatitis B and its aplication to various populations

**8. Were the patient recommendations based on acceptable practices in medicine?**

**(1)**

Yes <sup>(1-</sup>  
100.00%)

**10. Do you think the presentation was without commercial bias?**

**(1)**

Yes <sup>(1-</sup>  
100.00%)

**13. This seminar utilized a hybrid format where live lectures were supplemented by recorded pre and post-course presentations. What did you think of this approach and why? (1)**

I appreciate the live lectures. they are easier to understand and hold attention better than pre-recorded presentations.

As one of the participants of this educational activity, we want to encourage you to implement those ideas that were appropriate to your healthcare environment.

This evaluation is confidential and no individual will be identified by this office (Continuing Medical Education and Professional Development). It will only be used for quality improvement.

We look forward to seeing you at future University of Louisville events. Thank you very much.

---



**Prevention & Therapies for Hepatitis and Chronic Liver Disease Seminars 2022**

## October 1, 2022 - Indianapolis, IN

This activity was created to address the professional practice gaps listed below:

- Identifying current research studies on Hepatitis B, effective vaccines and promising therapeutic agents, which could help control the spread of the virus and reduce patient suffering.
- Identifying the early signs of Hepatitis A as many are caught off-guard about recent resurgence in many different populations and sub-groups.
- Recognizing that former HBV patients are at risk for contracting Hepatitis D.
- Applying clinical guidelines and best practice screening procedures and treatment approaches for end-stage liver disease (ESLD).
- Utilizing current and emerging technologies to determine liver disease that could reduce the need for invasive diagnostic testing.

### 1. Please respond regarding how much you agree or disagree that the gaps listed above were addressed.

	Disagree		Agree	
Participating in this educational activity changed your KNOWLEDGE in the professional practice gaps listed above. [7-3.86]	(0)	(0)	(1) 14.29%	(6) 85.71%
Participating in this educational activity changed your COMPETENCE in the professional practice gaps listed above. [7-3.71]	(0)	(0)	(2) 28.57%	(5) 71.43%
Do you feel participating in this educational activity will change your PERFORMANCE in the professional practice gaps listed above? [7-3.86]	(0)	(0)	(1) 14.29%	(6) 85.71%

### 2. Please elaborate on your previous answers. (3)

I am much more prepared to care for this population.

Great speakers. they were all able to relate very complex material to all of us and were very warm and answered all questions

The information provided during the conference helped me better cement the knowledge in my memory.

### 3. Please evaluate the effectiveness of the following speakers in improving your knowledge, competence and/or performance. (Poor = 1, Excellent = 4)

Poor      Fair      Good      Excellent

Raj Vuppalanchi, MD [7-4.00]	(0)	(0)	(0)	(7)100%
Marwan Ghabril, MD [7-4.00]	(0)	(0)	(0)	(7)100%
Lindsay Yoder, PA-C [7-4.00]	(0)	(0)	(0)	(7)100%

#### 4. Please elaborate on your previous answers. (4)

Field experts

Wonderful speakers

have known Dr V and G for a long time they are a good source of GI information in this state. Lindsay was good too

They all are extremely knowledgeable and very much willing to help others learn.

#### 5. Please identify a change that you will implement into practice as a result of attending this educational activity (new protocols, different medications, etc.) (6)

Healthier food options More mini brain breaks

viral hepatitis testing, NALFD management,HCC screening

I will check for hepatitis D and all patients with known hepatitis b.

learned a lot about SBP, HBV that would help me

none-currently doing this in clinical practice

I will make sure to test for co-infection if not already ruled out in every new hepatitis patient I have.

#### 6. How certain are you that you will implement this change?

(6)

Very Certain <sup>(5-</sup>  
83.33%)

N/A <sup>(1-</sup>  
16.67%)

#### 7. What topics do you want to hear more about, and what issues(s) in your practice will they address? (6)

How to interpret lab results and explain them to patients in a way they understand

abnormal liver test approach

colitis and how to treat.

HCV

none

Autoimmune hepatitis, lack of knowledge

**8. Were the patient recommendations based on acceptable practices in medicine?**

(7)

Yes <sup>(7-</sup>  
100.00%)

**10. Do you think the presentation was without commercial bias?**

(7)

Yes <sup>(7-</sup>  
100.00%)

**12. Please provide any additional comments you may have about this educational activity. (2)**

I did not like the lecture during lunch. It did not fit my practice.

it was thorough and comprehensive and covered most of hepatology subject

**13. This seminar utilized a hybrid format where live lectures were supplemented by recorded pre and post-course presentations. What did you think of this approach and why? (5)**

It was over lunch break, so there was not a chance to take a true brain break, which I needed.

I have not viewed the recorded presentations.

Live lectures are the way to go.

it was neat and new to me it was helpful

It is nice to have the recorded material to reference back to after the fact.

As one of the participants of this educational activity, we want to encourage you to implement those ideas that were appropriate to your healthcare environment.

This evaluation is confidential and no individual will be identified by this office (Continuing Medical Education and Professional Development). It will only be used for quality improvement.

We look forward to seeing you at future University of Louisville events. Thank you very much.



## Prevention & Therapies for Hepatitis and Chronic Liver Disease Seminars 2022

**October 8, 2022 - San Diego, CA**

This activity was created to address the professional practice gaps listed below:

- Identifying current research studies on Hepatitis B, effective vaccines and promising therapeutic agents, which could help control the spread of the virus and reduce patient suffering.
- Identifying the early signs of Hepatitis A as many are caught off-guard about recent resurgence in many different populations and sub-groups.
- Recognizing that former HBV patients are at risk for contracting Hepatitis D.
- Applying clinical guidelines and best practice screening procedures and treatment approaches for end-stage liver disease (ESLD).
- Utilizing current and emerging technologies to determine liver disease that could reduce the need for invasive diagnostic testing.

**1. Please respond regarding how much you agree or disagree that the gaps listed above were addressed.**

	Disagree		Agree	
Participating in this educational activity changed your KNOWLEDGE in the professional practice gaps listed above. [4-3.75]	(0)	(0)	(1) 25.00%	(3) 75.00%
Participating in this educational activity changed your COMPETENCE in the professional practice gaps listed above. [4-3.75]	(0)	(0)	(1) 25.00%	(3) 75.00%

Do you feel participating in this educational activity will change your PERFORMANCE in the professional practice gaps listed above? [4-3.75]

(0)	(0)	(1) 25.00%	(3) 75.00%
-----	-----	---------------	---------------

## 2. Please elaborate on your previous answers. (3)

N/a

great lecturers

more knowledge on HDV and NASH.

## 3. Please evaluate the effectiveness of the following speakers in improving your knowledge, competence and/or performance. (Poor = 1, Excellent = 4)

	Poor	Fair	Good	Excellent
Paul Pockros, MD [4-4.00]	(0)	(0)	(0)	(4)100%
Jennifer Au, MD [4-3.75]	(0)	(0)	(1) 25.00%	(3) 75.00%
Summer Collier, FNP [4-3.50]	(0)	(1) 25.00%	(0)	(3) 75.00%
Adam Deising, DO [4-3.75]	(0)	(0)	(1) 25.00%	(3) 75.00%

## 4. Please elaborate on your previous answers. (4)

N/a

all speakers were great and presented helpful info in an understandable way. Dr. Au's talk on HCC tx was my favorite talk.

knowledge was great

It's always great to listen to Dr. Pockros' lecture.

## 5. Please identify a change that you will implement into practice as a result of attending this educational activity (new protocols, different medications, etc.) (4)

Diagnostic testing

more routine screening for hep D in Hep B pts. Improved PBC & PSC identification and tx/management.

none

Assessing HDV status in each HBV patients.



**6. How certain are you that you will implement this change?**

(4)

Certain <sup>(2-</sup>  
50.00%)

Very Certain <sup>(2-</sup>  
50.00%)

**7. What topics do you want to hear more about, and what issues(s) in your practice will they address? (4)**

Not at this time

ascites fluid analysis, identifying SBP and pts who need prophylaxis. review of abd MRI/CT/US-normal and abnormal to assist in viewing our pt's imaging

general function and health

hepatitis B.

**8. Were the patient recommendations based on acceptable practices in medicine?**

(4)

Yes <sup>(4-</sup>  
100.00%)

**10. Do you think the presentation was without commercial bias?**

(4)

Yes <sup>(4-</sup>  
100.00%)

**12. Please provide any additional comments you may have about this educational activity. (4)**

N/a

Great speakers, good info, thank you.

I will attend next lecture(s)

Great conference.

**13. This seminar utilized a hybrid format where live lectures were supplemented by recorded pre and post-course presentations. What did you think of this approach and why? (3)**

Very good combination

it was not clear that there were pre-recorded sessions, and the were too early/late. It would be helpful to have clearer info re: the pre-recorded sessions and be able to view them prior to the mtg.

It's great to have additional optional lectures.

As one of the participants of this educational activity, we want to encourage you to implement those ideas that were appropriate to your healthcare environment.

This evaluation is confidential and no individual will be identified by this office (Continuing Medical Education and Professional Development). It will only be used for quality improvement.

We look forward to seeing you at future University of Louisville events. Thank you very much.

---